1. |
|
|
2. |
- Linderholm, B. K., et al.
(författare)
-
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
- 2013
-
Ingår i: Breast. - : Elsevier BV. - 1532-3080. ; 22:6, s. 1142-1147
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n = 7). Circulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined at base-line and before start of new course. Results: Fifty-five of 63 included patients were evaluable. The overall response rate including stable disease >= 24 weeks (CR + PD + SD) was obtained in 25 of the evaluable patients (45%). The median time to progression (TTP) was 5.3 months and overall survival (OS) 16.7 months. Patients with triple negative breast cancer (TNBC) showed a trend towards higher base-line VEGF compared with hormone receptor positive or HER2+ tumours and had shorter TTP. Significant differences in VEGF and bFGF levels at 12 weeks were found between patients with longer versus shorter TTP (VEGF: p = 0.046, bFGF: p = 0.005) and between patients gaining versus lacking clinical benefit (VEGF: p = 0.05, bFGF: p = 0.02). Conclusions: The clinical utility of circulating VEGF may be a useful tool for monitoring treatment efficacy. (C) 2013 Elsevier Ltd. All rights reserved.
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
- Eriksen, C, et al.
(författare)
-
Rebuttal letter
- 2011
-
Ingår i: BREAST CANCER RESEARCH AND TREATMENT. - 0167-6806. ; 129:1, s. 289-289
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
9. |
|
|
10. |
|
|